Collection, Cryopreservation and Autologous Transplantation of Peripheral Blood Stem Cells in Kaunas, Lithuania 2015-2019
| Author | Affiliation |
|---|---|
University of Leipzig, Germany, Leipzig, Germany |
| Date |
|---|
2020-08-29 |
Background: Peripheral blood stem cells (PBSCs) are widely used for autologous blood stem cell transplantation (auto-SCT) around the world. Post-thaw viable CD34+ cell count is the important parameter for quality assurance of the cryopreserved cells. The CD34+ cell post-thaw viability was analysed and its relationship with clinical parameters was evaluated in this study. Methods: The study included 236 apheresis, 329 products and 106 hematopoietic SCT on 100 patients undergoing auto-SCT in the Hospital of Lithuanian University of Health Sciences Kaunas Clinics from 2015 to 2019 August. Patient’s plasma and DMSO (final concentration of 10%) was used for PBSC cryopreservation. All PBSC products were initially cryopreserved in a controlled freezer, then stored in vapor phase nitrogen. PBSC were thawed before use in water bath at 37°C. Viability was assessed immediately after thawing using BD FACS Canto flow cytometer and BD Stem Cell Enumeration Kit. A multivariate regression model and Pearson correlation were applied for statistical analysis. Results: In total 100 patients (51 females, 49 males) with a median age of 59 (range 18-73) years were harvested after G-CSF (10 g/kg) or Cyclo+G-CSF or additional mobilizing agents such as plerixafor (0,24mg/kg, n=4) for auto-SCT. Indications were multiple myeloma (n=82), non-Hodgkin lymphoma (n=15), germ-cell testicular tumor (n=1), sarcoma (n=1) and autoimmune encephalitis (n=1). Most patients received one auto-SCT. 24 patients received double SCT and 1 patient triple SCT. PBSC transplantations were performed for patients with the following diagnosis: 94 myeloma, 7 lymphoma, 3 germ-cell testicular tumors, 1 CNS lymphoma and 1 autoimmune encephalitis. The median post-thaw CD34+ viability was 79% (range 42-96). Median leukocytes (>1.0 x 109/l) engraftment on two consecutive days was 11 (range 8-13) days, and 15 days for platelets (>50 x 109/l), ranging 9-23 days after [...].